Barbara Bumstead, NP
Adult Health · Bay Shore, NYNPI 1164497236
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (39.9%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 47 manufacturers reported payments, led by Biogen at 44.4% of the total. Reporting peaked in 2022 at $20,319 and has fallen 64.6% since, to $7,189 in 2025. Among adult health clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 460 payments — averaging $113.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$23K
- Amgen$7K
- Sanofi$5K
- E.r. Squibb & Sons, L.L.C.$3K
- Bristol Myers Squibb$3K
- TG Therapeutics, Inc.$3K
- plus $7K from 41 others
What the payments were for
- Consulting fees$11,92123%
- Speaking & faculty fees$20,76840%
- Travel & lodging$2,9436%
- Food & beverage$15,97131%
- Education$4051%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$52,007 in reported general payments places this provider in the 95th percentile of 3,828 adult health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 156 | $2,096,086 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 37 | $972,981 |
| VumerityDiroximel Fumarate | 38 | $570,110 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 24 | $330,143 |
| ZeposiaOzanimod Hydrochloride | 27 | $329,962 |
| Kesimpta PenOfatumumab | 32 | $311,549 |
| Avonex (4 Pack)Interferon Beta-1a | 26 | $211,273 |
| CopaxoneGlatiramer Acetate | 20 | $186,780 |
| AubagioTeriflunomide | 16 | $149,084 |
| Dalfampridine ErDalfampridine | 90 | $110,580 |
| Nurtec OdtRimegepant Sulfate | 45 | $104,648 |
| Tetrabenazine | 16 | $87,864 |
| NuplazidPimavanserin Tartrate | 13 | $87,679 |
| OxycontinOxycodone Hcl | 11 | $19,817 |
| HorizantGabapentin Enacarbil | 18 | $16,418 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $64 | $972,98137 claims |
| BiogenVumerity, Avonex (4 Pack) | $23,107 | $781,38364 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $3,480 | $329,96227 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $352 | $186,78020 claims |
| SanofiAubagio | $5,101 | $149,08416 claims |
| Acadia Pharmaceuticals IncNuplazid | $12 | $87,67913 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $81 | $16,41818 claims |
| Almatica Pharma LLCSertraline Hcl | $13 | $2,045114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,828 adult health providers in New York.
Other adult health in Bay Shore
- Donna CatameroNew York$279K
- Kristen DurkinPort Jefferson Station$255K
- Mary CiechoskiBuffalo$200K
- Jennifer FioriniGlens Falls$151K
- Katelyn McCormackAmherst$131K
- Maria Gigante-BaggettEast Syracuse$92K
- Jane PattersonRochester$66K
- Alyson HartyNew York$65K
- Danielle BrunoPlainview$61K
- Julie PlantamuraPort Jefferson Station$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.